Statins Reduce Interleukin-6–Induced C-Reactive Protein in Human Hepatocytes
- 1 June 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 25 (6), 1231-1236
- https://doi.org/10.1161/01.atv.0000163840.63685.0c
Abstract
Objectives— Besides its predictive role in determining cardiovascular risk, C-reactive protein (CRP) may exert direct proatherogenic effects through proinflammatory properties. CRP is mainly produced by hepatocytes in response to interleukin-6 (IL-6) and is then released into the systemic circulation. 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase inhibitors, or statins, significantly reduce cardiovascular events and mortality in patients with or without coronary artery disease and reduce plasma CRP levels in humans. However, the mechanism by which statins reduce plasma CRP levels remains unknown. Methods and Results— In this study, we report that statins limit both protein and RNA levels of IL-6-induced CRP in human hepatocytes. These effects are reversed by l -mevalonate and mimicked by an inhibitor of the geranylgeranyltransferase. IL-6–induced CRP production requires the binding of IL-6 to its cognate receptors, which results in activation and phosphorylation of the transcription factor STAT3. We provide evidence that statins reduce this IL-6–induced phosphorylation of STAT3 in hepatocytes. Conclusion— These results demonstrate that statins reduce IL-6–induced CRP production directly in hepatocytes via inhibition of protein geranylgeranylation. We further show that statins act via inhibition of STAT3 phosphorylation. These findings furnish new evidence for direct antiinflammatory properties of statins and provide new mechanistic insight into their clinical benefits.Keywords
This publication has 50 references indexed in Scilit:
- Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitroBlood, 2004
- Statins as Immunomodulatory AgentsCirculation, 2004
- C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth MuscleCirculation, 2003
- Fluvastatin Enhances the Inhibitory Effects of a Selective Angiotensin II Type 1 Receptor Blocker, Valsartan, on Vascular Neointimal FormationCirculation, 2003
- Inflammation in atherosclerosisNature, 2002
- Sequential Activation of Rac-1, SEK-1/MKK-4, and Protein Kinase Cδ Is Required for Interleukin-6-induced STAT3 Ser-727 Phosphorylation and TransactivationOnline Journal of Public Health Informatics, 2001
- ROLE OF STAT3 AND C/EBP IN CYTOKINE-DEPENDENT EXPRESSION OF THE MOUSE SERUM AMYLOID P-COMPONENT (SAP) AND C-REACTIVE PROTEIN (CRP) GENESCytokine, 2000
- Toward a theory regarding the pathogenesis of the systemic inflammatory response syndromeCritical Care Medicine, 1996
- TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT PathwayAnnual Review of Biochemistry, 1995
- Stat3: a STAT Family Member Activated by Tyrosine Phosphorylation in Response to Epidermal Growth Factor and Interleukin-6Science, 1994